Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 31st total of 8,400 shares. Based on an average trading volume of 16,800 shares, the short-interest ratio is presently 0.5 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its holdings in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent quarter. 1.34% of the stock is owned by hedge funds and other institutional investors.

Daxor Price Performance

DXR traded up $0.03 during mid-day trading on Tuesday, reaching $7.81. 557 shares of the stock were exchanged, compared to its average volume of 5,255. Daxor has a 1 year low of $7.19 and a 1 year high of $10.00. The company has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $8.73.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.